A5004006667- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cervical Cancer and HPV Research
- Uterine Myomas and Treatments
- Metabolism, Diabetes, and Cancer
- Endometriosis Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
- Adipose Tissue and Metabolism
- Cancer-related molecular mechanisms research
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- Cancer-related Molecular Pathways
- Ferroptosis and cancer prognosis
- TGF-β signaling in diseases
- Extracellular vesicles in disease
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Intraperitoneal and Appendiceal Malignancies
- DNA Repair Mechanisms
- Cancer Cells and Metastasis
- Colorectal and Anal Carcinomas
Oklahoma Cancer Specialists and Research Institute
2023-2024
University of Oklahoma Health Sciences Center
2015-2024
OU Health
2020-2023
Gynecologic Oncology Group
2022
University of Michigan
2022
Michigan Medicine
2022
University of Oklahoma
2007-2021
Oklahoma City University
2008-2021
Oklahoma State University Oklahoma City
2020
OU Health Stephenson Cancer Center
2012-2020
Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.
Purpose Women with abnormal cervical cancer screening results are referred to colposcopy and biopsy for diagnosis of precursors (high-grade squamous intraepithelial lesions [HSILs]). Colposcopy a single can miss identification HSILs. No systematic study has quantified the improved detection HSIL by taking multiple lesion-directed biopsies. Methods The Biopsy Study was an observational 690 women after results. Up four directed biopsies were taken from distinct acetowhite ranked colposcopic...
PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed activity two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy. PATIENTS AND METHODS NRG-GY004 an open-label, randomized, phase III trial conducted in United States and Canada. Eligible patients had high-grade serous endometrioid cancer. Patients were randomly assigned 1:1:1...
The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or immunohistochemistry (IHC). We examined the association between IHC and sequence whether alone, integrated with TP53 NGS, predicts outcome.From GOG-86P, randomized phase II study chemotherapy combined either bevacizumab temsirolimus advanced endometrial cancer, 213 cases had protein expression data measured NGS data. An analysis was designed to integrate presence absence mutation. These variables were further...
Purpose We conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma. Methods Women uterus-confined, high-grade leiomyosarcoma who were confirmed disease free by imaging randomly assigned four cycles of gemcitabine plus docetaxel, followed doxorubicin, or observation. All for evidence recurrence. The primary end point was overall (OS). Results With international collaboration, 38 the targeted accrual 216 patients...
Although hypoxia has been shown to reprogram cancer cells toward glycolytic shift, the identity of extrinsic stimuli that induce metabolic reprogramming independent hypoxia, especially in ovarian cancer, is largely unknown. In this study, we use patient-derived and high-grade serous cell lines demonstrate lysophosphatidic acid (LPA), a lipid growth factor GPCR ligand whose levels are substantially increased patients, triggers shift cells. Inhibition G protein α-subunit Gαi2 disrupted...
5505 Background: Patients with stage III/IVA uterine cancer (UC) carry high risk of systemic and local recurrence. Chemotherapy was shown to reduce recurrence, however the failure remains high. Methods: The primary endpoint this open label, randomized phase III trial determine if treatment cisplatin volume-directed radiation followed by carboplatin paclitaxel for 4 cycles (C-RT, experimental arm) reduces rate recurrence or death (i.e., increases recurrence-free survival, RFS) when compared 6...
Abstract Purpose: A phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune-modulation therapy with checkpoint inhibitor ipilimumab [anti–CTL antigen-4 (anti–CTLA-4)] following chemoradiation (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. To better understand mechanism action to identify predictive biomarkers, immunologic viral correlates were assessed before, during, after treatment. Patients Methods: Twenty-one...
Background Immune checkpoint inhibitors are being considered for locally advanced cervical cancer (LACC) together with standard‐of‐care pelvic chemoradiation (CRT). However, the safety of combination and its optimal schedule unknown. Defining is a primary objective study examining concurrent sequential schedules. This article presents analysis that was fully accrued met reporting requirements. Methods Pembrolizumab given after CRT (arm 1) or during 2) according to randomized phase 2 design....
6003 Background: Combination cediranib (C) and olaparib (O) improved progression-free survival (PFS) in patients (pts) with relapsed platinum (plat)-sensitive high-grade ovarian cancer (ovca) compared to O alone a Phase 2 trial (NCT01116648). We conducted this randomized, open-label 3 (NCT02446600) assess whether combination C+O, or alone, was superior standard of care (SOC) plat-based therapy plat-sensitive ovca. Methods: Eligible pts had recurrent [ > 6-month plat-free interval (PFI)]...
Purpose To assess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with contrast material-enhanced computed (CT) in detecting lymph node (LN) metastasis high-risk endometrial cancer. Materials and Methods This prospective multicenter HIPAA-compliant study had institutional review board approval, all participants gave written informed consent. Data were accrued between January 2010 June 2013. Patients underwent PET/CT pelvic abdominal...
With the goal of identifying diagnostic and prognostic biomarkers in endometrial cancer, miRNA-profiling was carried out with formalin-fixed paraffin embedded (FFPE) tissue samples from 49 cancer patients.Results using an 84-cancer specific miRNA panel identified upregulation miR-141-3p miR-96-5p along a downregulation miR-26, miR-126-3p, miR-23b, miR-195-5p, miR-374a let-7 family miRNAs cancer.We validated dysregulated expression cell-lines.Immunohistochemical analysis micro array derived...